公司资料
Immutep Limited 股价、新闻与催化剂
- 股票代码:
- IMMP
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Australia and listed in the U
股票表现
0.39 USD (+1.71%)
收盘价
最后更新: 2026年8月17日
61.3M USD
市值
股价为何变动
As of Aug 17, 2026, IMMP closed up 1.71% at $0.3865. No new same-company headline was identified in the current news window.
公司概览
业务概览
Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.
所在地与行业分类
Immutep is headquartered in Australia and listed in the U.S. market. It sits in small-cap oncology biotechnology.
商业模式特征
The company depends on clinical readouts, translational validation, and the ability to maintain a narrow immunotherapy pipeline. Investors usually watch efficacy signals and strategic collaborations.
生物医药行业定位
Immutep occupies a specialized immuno-oncology niche within biotech. The stock is catalyst-sensitive because the platform still needs to prove broad clinical relevance.
未来催化剂
- Immutep’s catalysts are eftilagimod alfa and the immuno-oncology program, where the next update can significantly shift sentiment. The company still needs human proof.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。